17 completed, 5 terminated, 3 not yet recruiting, 2 recruiting. 32 Phase 2, 6 Phase 3, 4 Phase 1.
Follow Comparator: new trials by email Literature Review of Comparator trials Research Report on Comparator
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in the Democratic Republic of the Congo Candidate BDBV vaccine, Active comparator - Ebola Hemorrhagic Fever, Bundibugyo Virus Disease | Phase 2 / Phase 3 | Not yet recruiting | Jean-Pierre Van geertruyden | 3620 | 2026-10-20 | 2026-10-05 |
| Efficacy of EMONO as an add-on Therapy to Conventional Antidepressants for the Treatment of Depressive Symptoms in Nursing-home Residents With Neurocognitive Disorders: a Randomized Controlled Trial- EMONO, Medical air - Depression, Neurocognitive Disorders | Phase 2 | Not yet recruiting | University Hospital, Tours | 96 | 2026-09-01 | 2026-06-17 |
| 61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET) 61Cu-NODAGA-LM3, Comparator - Neuroendocrine Tumors | Phase 1 / Phase 2 | Recruiting | University Hospital, Basel, Switzerland | 27 | 2025-02-05 | 2025-05-30 |
| Proof-of-concept to Evaluate the Efficacy and Safety of Prednisone in Idiosyncratic Hepatotoxicity Prednisone - Hepatotoxicity, Idiosyncratic Drug Effect | Phase 2 | Not yet recruiting | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | 60 | 2024-05-01 | 2024-04-05 |
| SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) SC1011, Placebo comparator - Idiopathic Pulmonary Fibrosis | Phase 2 / Phase 3 | Recruiting | Guangzhou JOYO Pharma Co., Ltd | 210 | 2023-06-06 | 2024-11-19 |
| A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer [177Lu]Lu-PSMA-617, ARDT, [68Ga]Ga-PSMA-11 - Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 63 | 2023-05-05 | 2026-03-23 |
| Application and Research of Mesenchymal Stem Cells in Alleviating Severe Development of COVID-19 Infection Umbilical cord mesenchymal stem cells implantation, Comparator - COVID-19 | Phase 1 / Phase 2 | Unknown | Hebei Medical University | 20 | 2023-01-28 | 2023-02-23 |
| The Safety and Efficacy of MoodElite T-4003-1 on Improving Mood in a Healthy Adult Population With Mild to Moderate Depressive Symptoms Not Eligible for Therapeutic Intervention MoodElite T-4003-1, Comparator, Placebo - Mood | Phase 1 / Phase 2 | Completed | Chenland Nutritionals Inc. | 44 | 2022-03-24 | 2023-03-22 |
| Investigation of the Efficacy and Safety of Three Test Products and Comparator on Muscular Performance After the Initiation of a Resistance Training Program Test Product 1, Test Product 2, Test Product 3 - Muscle Strength | Phase 2 | Completed | Roquette Canada, LTD. | 100 | 2021-04-01 | 2022-04-27 |
| Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis QBW251, Placebo - Bronchiectasis | Phase 2 | Terminated | Novartis Pharmaceuticals | 42 | 2021-02-02 | 2025-09-26 |
| An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2), Comparator - Influenza | Phase 2 / Phase 3 | Withdrawn | Seqirus | 2020-12-15 | 2021-03-23 | |
| Nitric Oxide Releasing Sinus Irrigation (NOSi) to Treat Recalcitrant Chronic Rhinosinusitis (RCRS) Nitric Oxide, Budesonide - Chronic Sinusitis | Phase 2 | Completed | Sanotize Research and Development corp. | 56 | 2019-10-27 | 2022-06-30 |
| AMZ001 for the Treatment of Knee Osteoarthritis Symptoms AMZ001, Placebo, Comparator - Osteoarthritis, Knee | Phase 2 / Phase 3 | Completed | Amzell | 444 | 2018-10-04 | 2020-10-06 |
| Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease AMX0035, Placebo - Alzheimer Disease | Phase 2 | Completed | Amylyx Pharmaceuticals Inc. | 95 | 2018-09-14 | 2025-03-07 |
| The Clinical Trial to Evaluate the Efficacy and Safety of CKD-497 CKD-497 200mg, CKD-497 300mg, CKD-497 placebo - Respiratory Infection | Phase 2 | Completed | Chong Kun Dang Pharmaceutical | 220 | 2018-05-29 | 2020-02-06 |
| Immune Effect of Dexmedetomidine in Patients Undergoing to Spinal Fusion Dexmedetomidine intervention, Placebo - Spine; Arthrosis, Spondylolysis | Phase 2 / Phase 3 | Unknown | Sarah Network of Rehabilitation Hospitals | 46 | 2016-08-01 | 2016-08-23 |
| Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis Dalbavancin, Comparator - Osteomyelitis | Phase 2 | Completed | Durata Therapeutics Inc., an affiliate of Allergan plc | 80 | 2016-03-15 | 2019-01-04 |
| Pilot Study of a Combination Drug Product for Treatment of Short-term Insomnia SM-1, Comparator, Placebo - Short-term Insomnia | Phase 2 | Completed | Sequential Medicine Ltd | 39 | 2016-02-01 | 2018-03-06 |
| Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss AUT00063, Placebo - Age-Related Hearing Loss | Phase 2 | Completed | Autifony Therapeutics Limited | 78 | 2015-01-01 | 2018-08-09 |
| Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR Ticagrelor, Comparator - Peripheral Artery Disease (PAD) | Phase 2 | Terminated | AstraZeneca | 40 | 2014-10-20 | 2017-07-19 |
Showing 20 of 32. Sign in to see all of them.
Alzheimer Disease (1) · Ankylosis (1) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Bronchiectasis (1) · Bronchitis (1) · COVID-19 (1) · Cardiovascular Diseases (1) · Community-Acquired Pneumonia (1) · Coronary Artery Disease (1) · Depression (1) · Diabetes Mellitus, Type 2 (1) · Hearing Loss (1) · Heart Diseases (1) · Hemorrhagic Fever, Ebola (1)
Allergopharma GmbH & Co. KG (4) · Autifony Therapeutics Limited (2) · Novartis Pharmaceuticals (2) · Tecno Sun SRL (2) · Amylyx Pharmaceuticals Inc. (1) · Amzell (1) · Andre Denault (1) · AstraZeneca (1) · CDA Research Group, Inc. (1) · Chenland Nutritionals Inc. (1) · Chiesi Farmaceutici S.p.A. (1) · Chong Kun Dang Pharmaceutical (1) · Durata Therapeutics Inc., an affiliate of Allergan plc (1) · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (1) · Guangzhou JOYO Pharma Co., Ltd (1)
Canada (5) · United States (5) · China (4) · Germany (4) · United Kingdom (3) · Italy (2) · Ukraine (2) · Brazil (1) · Chile (1) · Croatia (1) · Czechia (1) · Democratic Republic of the Congo (1) · Denmark (1) · Estonia (1) · Mexico (1)
David Crowley, MD (2) · Amin Javer, MD (1) · Ashwin Chatwani, MD (1) · Baoyong Yan, Master (1) · Dave Singh, MD (1) · Deepen Patel, MD, CCFP (1) · Ding Yu, Master (1) · Gang Liu, Master (1) · Guillaume Nicolas, Dr. (1) · Jaydip Ray, MD (1) · Jiawei Yang, Postgraduate (1)
PMID 23621350, PMID 24041858, PMID 25329189, PMID 27109816, PMID 27470232, PMID 29629845, PMID 29859173, PMID 30648126, PMID 30939361, PMID 31837050, PMID 31978293, PMID 31986257, PMID 32085846, PMID 32257537, PMID 32811531, PMID 33514427, PMID 34750382, PMID 37941072, PMID 39131742
2023 (2), 2008 (1)